We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems,... read more Featured Products: More products

Download Mobile App




GE Healthcare and Affibody Collaborate to Develop PET Imaging Tracers

By MedImaging International staff writers
Posted on 26 Sep 2019
Print article
GE Healthcare (Chicago, IL, USA) and Affibody AB (Solna, Sweden) have entered into a strategic collaboration to develop and commercialize Affibody-based PET imaging tracers, with initial focus on HER2 and PD-L1.

Affibody is a clinical stage biopharmaceutical company focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody molecules and Albumod. Affibody operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis, and B-cell driven autoimmune diseases, respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

The Affibody technology is uniquely suited for the development of PET imaging tracers and ABY-025, a HER2-detecting Affibody-based PET imaging tracer, is currently in clinical development. ABY-025 provides a novel non-invasive and cost-effective approach to diagnose global HER2-expression in metastatic breast cancer patients using PET imaging. Affibody is currently working together with academic institutions to explore the clinical utility of ABY-025 further. The PD-L1 binding Affibody molecule is being developed as a diagnostic tool to improve selection and monitoring of patients with immuno-oncology treatments. The collaboration with GE Healthcare will accelerate studies through to a stage of clinical proof of concept.

“The initiation of a strategic collaboration with GE Healthcare around PET imaging tracers reflects the commitment of Affibody to precision medicine and biomarker guided patient treatment. It also underlines the competitiveness of our technology and the value of the clinical data that has been generated with Affibody-based imaging agents,” said David Bejker, CEO of Affibody. “We believe that our collaboration with GE Healthcare to develop and commercialize these imaging agents will make a significant contribution to enhance the treatment of cancer patients globally.”

“We recognize that PET imaging plays a vital role in the development and use of cancer immunotherapies as it is a non-invasive way to measure patient response before, during and after treatment,” said Sanka Thiru, Head of Molecular Imaging Oncology, in GE Healthcare’s Pharmaceutical Diagnostics business. “We are partnering with companies like Affibody to build a portfolio of molecular imaging agents for oncology, focusing on those disease biomarkers that will help accelerate the development of the next generation of cancer treatments.”

New
Gold Supplier
Electrode Solution and Skin Prep
Signaspray
Gold Supplier
Ultrasound System
FUTUS LE
New
PACS Workstation
PaxeraView PRO
New
Mobile Imaging Table
medifa 8000 hybrid

Print article
Radcal

Channels

Radiography

view channel
Image: Intelligent NR provides high-quality diagnostic images containing significantly less grainy noise (Photo courtesy of Canon)

AI-Driven DR System Produces Higher Quality Images While Limiting Radiation Doses in Pediatric Patients

Ionizing radiation is a fundamental element in producing diagnostic X-rays, yet it's widely acknowledged for its cancer risk potential. Digital projection radiography, a vital imaging modality, accounts... Read more

MRI

view channel
Image: Innovative design has helped achieve a tenfold better resolution for functional MRI brain imaging (Photo courtesy of UC Berkeley)

Ultra-High Resolution 7 Tesla Scanner Records Over 50 Times More Detail than Current 3T Scanners

Mental disorders significantly impact individuals, families, and society at large. Despite being fundamentally disorders of brain function, most mental disorders are currently diagnosed based on behavioral... Read more

Ultrasound

view channel
Image: The HydroMARK Plus Breast Biopsy Site Marker is an Innovation for tissue marker displacement (Photo courtesy of Mammotome)

Innovative Biopsy Marker Provides Clinicians with Long-Term Ultrasound Visibility

Ultrasound is the preferred choice for core biopsy as it provides a real-time view of both the lesion and needle, enabling clinicians to make prompt decisions for their patient’s benefit and improve procedural... Read more

Nuclear Medicine

view channel
Image: A novel PET radiotracer facilitates early, noninvasive detection of IBD (Photo courtesy of Karmanos)

New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is an inflammatory condition of the gastrointestinal tract affecting roughly seven million individuals globally.... Read more

General/Advanced Imaging

view channel
Image: The innovative technology is cheaper and safer than common cancer diagnostic tools (Photo courtesy of University of Waterloo)

Innovative Technology Detects Early-Stage Breast Cancer in Two Minutes

Breast cancer is the second-most common cancer and among the second-leading causes of death from cancer for women. The sooner a malignant tumor is detected, the higher the chances of survival in breast... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.